Intervention

Pasireotide LAR

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions10

Lead sponsors shown2

Clinical trials

2 shown

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialNCT01563354 · 2013-08-16

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesNCT01794793 · 2013-06-10

Common conditions

Acromegaly1 Cushing's Disease1 Dumping Syndrome1 Ectopic ACTH Secreting (EAS) Tumors1 Melanoma Negative for bRAF1 Melanoma Negative for nRAS1 Neuroendocrine Carcinoma of the Lung and Thymus1 Neuroendocrine Tumors1 Pituitary Tumors1 Prostate Cancer1

Leading sponsors

Novartis Pharmaceuticals1 RECORDATI GROUP1

Trial status mix

COMPLETED2

Phase mix

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.